Systematic Financial Management LP Increases Holdings in Supernus Pharmaceuticals, Inc. $SUPN

Systematic Financial Management LP boosted its stake in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 4.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 304,226 shares of the specialty pharmaceutical company’s stock after buying an additional 11,966 shares during the period. Systematic Financial Management LP owned 0.53% of Supernus Pharmaceuticals worth $15,120,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also made changes to their positions in SUPN. Royal Bank of Canada increased its position in shares of Supernus Pharmaceuticals by 68.1% in the 1st quarter. Royal Bank of Canada now owns 11,669 shares of the specialty pharmaceutical company’s stock valued at $382,000 after acquiring an additional 4,729 shares during the period. AQR Capital Management LLC increased its position in shares of Supernus Pharmaceuticals by 35.2% in the 1st quarter. AQR Capital Management LLC now owns 85,224 shares of the specialty pharmaceutical company’s stock valued at $2,791,000 after acquiring an additional 22,182 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of Supernus Pharmaceuticals by 4.5% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 29,860 shares of the specialty pharmaceutical company’s stock valued at $978,000 after acquiring an additional 1,297 shares during the period. Millennium Management LLC increased its position in shares of Supernus Pharmaceuticals by 370.5% in the 1st quarter. Millennium Management LLC now owns 143,356 shares of the specialty pharmaceutical company’s stock valued at $4,695,000 after acquiring an additional 112,886 shares during the period. Finally, Empowered Funds LLC increased its position in shares of Supernus Pharmaceuticals by 16.0% in the 1st quarter. Empowered Funds LLC now owns 48,045 shares of the specialty pharmaceutical company’s stock valued at $1,573,000 after acquiring an additional 6,619 shares during the period.

Analyst Ratings Changes

Several equities research analysts have weighed in on SUPN shares. Craig Hallum set a $65.00 price target on Supernus Pharmaceuticals in a research report on Wednesday, February 25th. Wall Street Zen downgraded Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday. Zacks Research raised Supernus Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Monday, April 27th. Finally, Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a research report on Friday, March 27th. Four equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $62.17.

Supernus Pharmaceuticals Price Performance

SUPN opened at $48.21 on Monday. The company’s 50 day simple moving average is $49.99 and its two-hundred day simple moving average is $49.64. Supernus Pharmaceuticals, Inc. has a 1-year low of $30.83 and a 1-year high of $59.68. The firm has a market capitalization of $2.80 billion, a price-to-earnings ratio of -94.53, a price-to-earnings-growth ratio of 1.04 and a beta of 0.57.

Insider Buying and Selling at Supernus Pharmaceuticals

In other Supernus Pharmaceuticals news, CEO Jack A. Khattar sold 35,000 shares of the firm’s stock in a transaction that occurred on Friday, March 13th. The shares were sold at an average price of $50.37, for a total value of $1,762,950.00. Following the transaction, the chief executive officer directly owned 958,100 shares of the company’s stock, valued at $48,259,497. This trade represents a 3.52% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Georges Gemayel sold 10,000 shares of the company’s stock in a transaction dated Thursday, March 5th. The shares were sold at an average price of $53.71, for a total transaction of $537,100.00. Following the completion of the sale, the director directly owned 28,159 shares of the company’s stock, valued at $1,512,419.89. This represents a 26.21% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 116,406 shares of company stock valued at $5,911,086. Company insiders own 8.80% of the company’s stock.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.